{"retracted":false,"update":{"timestamp":1469404800000,"doi":"10.1186/s12885-016-2559-8","type":"correction"},"doi":"10.1186/s12885-016-2440-9","journal":"BMC Cancer","publisher":"Springer Nature","title":"Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program"}
